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Summary
Background: Primary care practitioners (PCPs) and diabetologists are at the frontline 
of potentially encountering patients with NASH. Identification of those at high risk 
for adverse outcomes is important.
Aim: To provide practical guidance to providers on how to identify these patients and 
link them to specialty care.
Methods: US members of the Global Council on NASH evaluated the evidence about 
NASH and non-invasive tests and developed a simple algorithm to identify high-risk 
NASH patients for diabetologists and primary care providers. These tools can assist 
frontline providers in decision-making and referral to gastroenterology/hepatology 
practices for additional assessments.
Results: The presence of NASH-related advanced fibrosis is an independent predic-
tor of adverse outcomes. These patients with NASH are considered high risk and re-
ferral to specialists is warranted. Given that staging of fibrosis requires a liver biopsy, 
non-invasive tests for fibrosis would be preferred. Consensus recommendation from 
the group is to risk-stratify patients based on metabolic risk factors using the FIB-4 
as the initial non-invasive test due to its simplicity and ease of use. A FIB-4 score ≥1.3 
can be used for further assessment and linkage to specialty care where additional 
technology to assess liver stiffness or serum fibrosis test will be available.
Conclusion: Due to the growing burden of NAFLD and NASH, PCPs and diabetolo-
gists are faced with increased patient encounters in their clinical practices neces-
sitating referral decisions. To assist in identifying high-risk NASH patients requiring 
specialty care, we provide a simple and easy to use algorithm.
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1  | INTRODUC TION
From 2015 to 2017, reports from the Center for Disease Control 
(CDC) indicated that the average life expectancy in the United 
States (US) has declined mostly due to deaths from drug overdose 
and suicide.1,2 Although this mortality rate has now levelled off, 
chronic diseases remain among the most common causes of death 
in the US. In this context, obesity (defined as a body mass index 
[BMI] ≥30 kg/m2 in Western Countries or 27.5 kg/m2 in Eastern 
Countries) is an important risk for a number of chronic diseases 
such as cardiovascular diseases, cancers, diabetes (T2DM), and 
non-alcoholic fatty liver disease (NAFLD).3-6 The most recent esti-
mates suggest that almost 40% of adults in the US are obese, and 
obesity is one of the five most common risk factors for global mor-
tality. In fact, the presence of obesity seems to decrease lifespan 
by 3-8 years, and the addition of diabetes to obesity will reduce 
lifespan by up to 20 years.7,8
In the context of this rising epidemic of obesity, the worldwide 
prevalence of NAFLD is estimated to be 25%.9 However, the prev-
alence can be higher, ranging from 30% up to 90% based on certain 
risk factors (body composition, presence T2DM, ethnicity, age) and 
the modality used to establish the diagnosis of NAFLD.6,10-13 In fact, 
obesity (regardless of presence of other metabolic factors) is an in-
dependent risk factor for NAFLD, and individuals with obesity are at 
four-folds higher risk of having NAFLD as compared to individuals 
with normal weight.14,15 The relationship between increase in weight 
and risk of NAFLD is dose dependent. In fact, there is a 20% increase 
risk for NAFLD with for every unit increase in BMI.16 In addition to 
obesity, T2DM is another strong risk factor for NAFLD. In a recent 
meta-analysis, the prevalence of NAFLD among patients with T2DM 
was found to be 55.5%.17
Although, NAFLD is a manifestation of metabolic diseases such 
as visceral obesity and T2DM, it has been histologically segregated 
into non-alcoholic fatty liver (isolated hepatic steatosis, NAFL) or 
non-alcoholic steatohepatitis (NASH) which is defined as steatosis 
combined with histological features of necroinflammation. Typically, 
patients with NASH and advanced hepatic fibrosis are those at sig-
nificant risk for liver-related complications (end-stage liver disease, 
hepatocellular carcinoma [HCC] and liver transplantation).18-20 
Indeed, numerous studies have shown that the stage of liver fibrosis 
is the most important determinant of patient outcomes and mortal-
ity.18-21 Considering invasiveness of liver biopsy and the large num-
ber of potential patients with NAFLD in the community, liver biopsy 
is not a practical tool to assess the stage of liver disease in NASH. 
Over the last several years, established non-invasive tools (NITs) 
have been used to estimate the stage of liver disease in NASH. These 
NITs have been found to be helpful to clinicians with the identifica-
tion of patients at high risk with NASH so that targeted management 
and long-term monitoring can be accomplished.22
On the other hand, it is important to note that the symptomatol-
ogy of patients with NASH is not always clinically helpful. Although 
NASH patients can have fatigue, their symptoms are usually non-
specific such that all too often patients are not suspected of having 
liver disease until they develop advanced stages of cirrhosis. In many 
instances, patients with NASH, may have had years of minimally ele-
vated alanine aminotransferase (ALT) levels that had been under-ap-
preciated as potentially reflective of a progressive liver disease.23,24 In 
other cases, disease progression may have occurred in the absence of 
any abnormality of aminotransferases. In 2020, despite the high prev-
alence of NAFLD in the general population, only a very small propor-
tion of patients are identified in the primary care setting in the US.25
As a result, these patients are primarily seen in gastroenterology 
and hepatology practices with advanced disease including cirrhosis 
and HCC. In this context, NASH has now become the second lead-
ing indication for liver transplantation (LT) in the US, while being 
the most common LT indication among women.26,27 Furthermore, 
NASH is recognised not only as the third most common, but also 
as the most rapidly growing aetiological causes of HCC in the US.28 
Therefore, these data suggest that the hepatic consequences of 
NASH are already being experienced in clinical practices in the US.
In order to manage this significant public health and clinical chal-
lenge, it is becoming increasingly clear that NASH patients who are 
at highest risk for progressive liver disease must be identified early 
in their course of disease. In this context, an efficient screening and 
linkage to the appropriate care strategy to identify these patients 
from primary care and diabetology practices and link them to ‘liver 
disease’ care is important.25,29,30 This paper provides a summary of 
a recent meeting by the US members of the Global NASH Council 
to raise awareness about NAFLD and develop a simple and easy to 
use algorithm to help with the identification of high-risk patients by 
primary care providers (PCPs) and non-hepatology specialists.
2  | WHAT IS NON-ALCOHOLIC FAT T Y 
LIVER DISE A SE?
NAFLD is a spectrum of hepatic pathology that includes non-alco-
holic fatty liver (NAFL), defined as >5% of steatosis found within 
the liver cells but without concurrent inflammation or liver cell 
injury. NASH is histologically distinct from NAFL, and is charac-
terised by hepatic inflammation and cellular injury in addition to 
steatosis, with potential of progression to fibrosis and cirrhosis. 
The necroinflammatory features of NASH on histology include a 
distinctive form of liver injury characterised by cellular balloon-
ing of hepatocytes, often including lobular inflammation, varying 
degrees of hepatic fibrosis and sometimes Mallory-Denk bodies 
within hepatocytes. Unlike chronic viral or immune-mediated 
hepatitis, the fibrotic process in NASH begins in the centrilobu-
lar rather than portal areas, though portal fibrosis may occur as 
the disease progresses.31 NASH cirrhosis (fibrosis stage 4/4) is 
the result of progressive fibrosis and can result in progressive 
synthetic dysfunction of the liver and can be initially seen as the 
development of portal hypertension. All forms of NAFLD can be 
asymptomatic and detected either incidentally by imaging or by in-
vestigating incidental elevation of liver enzymes. It is important to 
note that a large proportion of individuals with NAFLD (including 
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NASH and NASH cirrhosis) may have normal liver enzymes, and 
the elevation of liver enzymes cannot be used to distinguish the 
spectrum of NAFLD.31
3  | EPIDEMIOLOGY OF NAFLD
As mentioned above, the global prevalence of NAFLD exceeds 
25% of all adults, although there is significant geographical varia-
tion. South America and the Middle East have the highest reported 
NAFLD prevalence of more than 30%, while Africa has the lowest 
NAFLD prevalence of 13%.9 Asia, due in part to rapid urbanisation, 
also has a high (27%-29%) and growing prevalence of NAFLD.32 More 
relevant to clinical practice may be the prevalence of progressive 
form of NAFLD which is NASH.33 In the US, the prevalence of NASH 
in the general population is estimated to be between 1.5 and 6.5%.9
The rising epidemic of obesity and T2DM is fueling the disease 
burden of NASH. In one modelling study, the number of NASH pa-
tients in the US and European Union (EU) was estimated at 28.9 
million while 5.8 million NASH patients were considered to have ad-
vanced fibrosis (F3/F4). It was estimated that the number of NASH 
patients with advanced fibrosis in the US will double by 2030.34
Although the majority of patients with NAFLD present with obe-
sity, about 30% of patients with NAFLD are either of normal weight 
(BMI <25 kg/m2 for Western countries and <23 kg/m2 for Eastern 
countries) or can be considered as nonobese (BMI <30 kg/m2 for 
Western countries and 25-27 kg/m2 for Eastern countries).9,35 The 
prevalence of lean NAFLD in the US general population is about 
7.4%.36 This group may be significantly higher in other popula-
tions such as those who reside in the rural areas of Asian countries. 
Despite these estimates, it is important to note that BMI is not a very 
accurate reflection of body composition and abdominal adiposity is 
a better estimate. Furthermore the so called lean NAFLD patients 
are still metabolically abnormal with evidence for insulin resistance 
and abdominal adiposity. In this context, metabolically normal lean 
NAFLD is less common in the general population.33
As noted previously, T2DM is another strong risk factor for 
NAFLD. In fact, adults with NAFLD frequently have concurrent met-
abolic disease with 30% having insulin resistance or T2DM, ≥50% 
having hypertension, hyperlipidemia or metabolic syndrome.9 The 
global prevalence of NAFLD among patients with T2DM is estimated 
to be about 55.5% (95% CI 47.3-63.7). On the other hand, the prev-
alence of NASH among those with T2DM is 37.3% (24.7%-50.0%) 
while the estimated prevalence of advanced fibrosis in NAFLD pa-
tients with T2DM is 17.0% (95% CI 7.2-34.8).17
Another interesting aspect of NAFLD is the ethnic heterogeneity 
in the prevalence of NAFLD. In this context, Hispanic and Caucasian 
males are more likely to have NAFLD, whereas African Americans 
are at a lower risk for NAFLD. A suggested reason for a lower risk of 
NAFLD among African Americans i potentially due to a lower rate 
of the genetic variant in the patatin-like phospholipase domain-con-
taining 3 gene (PNPLA3) which has been associated with higher prev-
alence of NAFLD and more progressive disease.37,38
PNPLA3 gene encodes for a triglyceride hydrolase, and genetic 
polymorphisms of this gene exert a strong influence on hepatic fat 
accumulation, with affected individuals having up to a 73% increased 
hepatic fat content, which increases susceptibility to the development 
of severe histological liver damage and liver fibrosis independent of 
the degree of obesity or the presence of diabetes. It appears that this 
single variant in the PNPLA3 gene, I148M, is found in greater frequency 
in Hispanics and non-Hispanic whites, but less frequently in African 
Americans.37-39 Testing for this variant is not widely available and algo-
rithms for incorporating it into practice have not yet been developed.
4  | NATUR AL HISTORY OF NAFLD
The majority of patients with NAFLD do not progress to cirrhosis. 
However, around 10%-15% of patients with histological NASH can 
progress to cirrhosis and will be at risk for hepatocellular carci-
noma, liver transplantation or death.6,40-43 Risk factors for progres-
sion include T2DM, insulin resistance and the other components of 
metabolic syndrome. In fact, the more components of metabolic syn-
drome, the higher the risk of advanced liver disease and mortality.44
There are a number of important issues related to long-term out-
comes in the context of NASH. First, cardiovascular disease (CVD) 
mortality is the most common cause of death until patients reach ad-
vanced stages of NASH with cirrhosis where liver mortality becomes 
the predominant cause of death.45 Therefore, it is of utmost impor-
tance that optimal management of the cardiometabolic risk factors in 
patients with NAFLD be obtained. Second, progression of fibrosis in 
NASH is not linear or unidirectional. In fact, patients can progress and 
regress spontaneously. This phenomenon has led to surprisingly high 
placebo rates in clinical trials of NASH with rates ranging between 10% 
and 40% and perhaps higher.46 Third, patients with NASH can develop 
HCC with or without cirrhosis.40,47,48 The HCC event rate for fibrosis 
stage 3 and fibrosis stage 4 stages have been reported to be 3.7 and 2.9 
per 1000 person-years respectively in the US and EU, while in Asia the 
reported HCC rate was 1.8 cases per 1000 person-years with an overall 
mortality rate of 5.3 deaths per 1000 person-years. However, the rate 
of HCC in NAFLD without cirrhosis is 0.5 cases 1000  person-years.47 
Given the relatively higher rates of HCC in NASH cirrhosis, these pa-
tients should be screened according to AASLD guidelines for HCC 
screening.49 In contrast, the rate of HCC among those with NASH 
without cirrhosis is low so the current guidelines do not support HCC 
screening for patients with noncirrhotic NASH.52 In addition to risk of 
HCC, stage of fibrosis is important for future treatment options. In this 
context, identifying NASH patients at high risk for fibrosis is of clinical 
importance not only so proper HCC screening can be implemented, but 
also to better identify patients who may be candidates for drug therapy 
when available.
Patients with NAFLD are at increased risk for extrahepatic 
cancers, including colon, gastric and pancreatic cancers.50,51 
Furthermore, they also experience impairment of health-related 
quality of life (HRQL) and other patient-reported outcomes, specifi-
cally fatigue and work productivity.23,24
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As noted previously, the increasing epidemic of obesity is expected 
to lead to a significant rise in the prevalence of NAFLD. In fact, a re-
cent modelling study from the US suggested that NAFLD is projected 
to increase by 21% (100.9 million cases) by 2030 leading to an overall 
prevalence among adults (≥15 years old) of almost 34%. NASH has been 
forecasted to increase 63% to 27.00 million cases while the incidences 
of decompensated cirrhosis, HCC and liver-related deaths will increase 
168%, 137% and 178% respectively. These changing trends are pro-
jected to result in approximately 800 000 excess liver deaths in the US.52
5  | PREDIC TORS OF DISE A SE 
PROGRESSION IN NAFLD
Currently, patients with NASH and advanced fibrosis (termed ‘bridg-
ing fibrosis’ or F3 on a scale of F0-F4) and those with cirrhosis (F4) 
are in most urgent need for intervention.41,42 In addition, there are 
multiple studies suggesting that NAFLD patients with T2DM are 
at risk for increased mortality.53,54 In fact, the larger the number 
of components of metabolic syndrome, the higher the risk of mor-
tality.44 In combination, if an algorithm can non-invasively identify 
NAFLD subjects with more advanced stages of fibrosis and meta-
bolic derangements, these patients are considered to be at the 
greatest risk for progressive liver disease and adverse clinical out-
comes. Notably, although a variety of NIT's that distinguish NAFL 
(steatosis) from NASH (steatohepatitis) have been studied, including 
biomarkers and refinements in MRI techniques, none are of proven 
value in clinical practice.22 In contrast, there is extensive literature 
on serological and imaging tests that have been incorporated into 
clinical practice to assess fibrosis stage on which the following dis-
cussion will focus.22 Therefore, the value of non-invasive tests (NITs) 
is currently focused on their ability to accurately stage liver disease 
rather than establish the diagnosis of NASH.
6  | STAGING FIBROSIS IN NAFLD: LIVER 
BIOPSY
Liver biopsy remains the gold standard to assess liver fibrosis stage 
and establish the histological diagnosis of steatohepatitis. However, 
liver biopsy is limited due to its invasiveness, sampling error, cost 
and inter-/intraobserver variability of pathologic interpretation.55,56 
Furthermore, due to the epidemic nature of NAFLD worldwide, rou-
tine evaluation using liver biopsy as the first step in diagnosis and 
staging of NASH is impractical and unwarranted.
7  | STAGING FIBROSIS IN NAFLD: NON-
INVA SIVE TESTS
Given the short coming of liver biopsy, efforts have been undertaken 
to develop NITs to diagnose NASH and stage fibrosis. Most NITs to 
establish the diagnosis of NASH have not been fruitful so efforts have 
focused on identifying accurate methods to establish NITs for fibrosis 
using serum and radiologic-based biomarkers.61 This is partly based on 
the evidence that stage of fibrosis is the best predictor of liver disease 
progression and long-term outcomes.18,19,21 Additionally, these NITs 
can be used to reduce the number of inappropriate referrals to spe-
cialists for additional evaluation and for liver biopsy considerations. 
Well-validated NITs can also potentially lead to better clinical out-
comes, substantial economic savings, reduced burdens on specialty 
clinics as well as reducing patient anxiety and inconvenience.57-62
One simple test is serum aminotransferases and their role in screen-
ing for NASH. On the other hand, it is important to note that aspartate 
aminotransferase (AST) and ALT levels are often normal in patients 
with NASH, and do not correlate with severity or activity of disease 
in patients with NASH.62-66 Nevertheless, the presence of an AST:ALT 
ratio >1 should raise concern about the presence of significant hepatic 
fibrosis. Some of the other currently available NITs, components of 
each tests, their accuracy and clinical use are listed in the Table 1.
7.1 | Fibrosis-4 test (FIB-4)
The FIB-4 score was developed to diagnose fibrosis and is best 
used to distinguish fibrosis stage 0-2 from fibrosis stage 3-4 (ad-
vanced fibrosis).67 The FIB-4 score is derived from common labo-
ratory results: AST, ALT and platelet count in addition to age. The 
FIB-4 can be easily calculated online at https://www.mdcalc.com/
fibro sis-4-fib-4-index -liver -fibrosis and is derived from the formula: 
FIB-4 = Age (years) × AST (U/L)/[PLT(109/L) × ALT1/2 (U/L)].
At a cut-off score of <1.3 the FIB-4 has a negative predictive 
value (NPV) of 90%-95% for F3-F4 fibrosis and an accuracy of 68%, 
while a cut-off score of >2.67 has an 80% positive predictive value 
(PPV) for F3-F4. However, given the potential uncertainty that may 
arise around the grey zone of <1.3 and >2.67, it is the recommenda-
tion of the NASH Council that a patient who has a FIB-4 score of >1.3 
be referred to a specialist and for those that have a score ≤1.3 un-
dergo lifestyle intervention with their primary provider (Figure 1).67
As age is a variable in calculation of FIB-4, the score increases with 
increasing age. Additionally, as age increases, ALT levels are often lower, 
so that for those over the age of 65 years old, a FIB-4 score of >2.0 should 
be used as the cut-off at which to refer so those with a score of <2.0 need 
not be referred (Figure 1).68,69 Conversely, for those under the age of 35, 
the FIB-4 score may not be as accurate, and therefore, other factors such 
as family history of NASH cirrhosis, the number of metabolic syndrome 
components present or the presence of T2DM should be taken into con-
sideration when deciding whether to refer to a specialist.
7.2 | NAFLD fibrosis score (NFS)
Using age, the presence of impaired fasting glucose or diabetes, BMI, 
platelet count, albumin and AST/ALT ratio, the NFS is an independ-
ent predictor of advanced liver fibrosis, with receiver operating char-
acteristic (ROC) of 0.88 and 0.82 in the estimation and validation 
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groups, respectively.70 At a low cut-off score of −1.455, the score 
had NPV of 93% for advanced fibrosis in the estimation group and 
88% in the validation group. At a high cut-off score of 0.676, NFS 
had a PPV for advanced fibrosis of 90% in the estimation group and 
82% in the validation group. The authors concluded that the NFS 
score could avoid liver biopsy in 75% of patients. The accuracy of 
the NFS in predicting the fibrosis stage is 67.5%-100% for those 
aged 35-64 years old.70 However, despite the good parameters of 
the NFS, there remains an indeterminate zone between −1.455 and 
0.676 in which practitioners will have to make a judgment call as to 
whether further testing is necessary.70,71 The NFS can be calculated 
online at https://www.mdcalc.com/nafld -non-alcoh olic-fatty -liver - 
disea se-fibro sis-score. The formula is NFS = −1.675 + 0.037 × age 
(years) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, 
no = 0) + 0.99 × AST/ALT ratio − 0.013 × platelet (×109/l) − 0.66 × al-
bumin (g/dL).
7.3 | AST to platelet ratio index: APRI
Previously, the use of AST to platelet ratio index (APRI) had been 
suggested to be useful in clinical practice for those with NAFLD. The 
sensitivity and specificity of a score >1 for significant fibrosis were 
30.0% (95% CI: 17.2-45.4%) and 92.8% (95% CI: 88.2%-95.8%) re-
spectively. However, the APRI cannot discriminate between interme-
diate stages of fibrosis. Additionally, a more recent study suggested 
that APRI did not perform as well of FIB-4 or NFS.72 Therefore, the 
most recent NAFLD guidance from the American Association for 
the Study of Liver Disease (AASLD) does not recommend the use 
of APRI in evaluating advanced fibrosis in patients with NAFLD.22
7.4 | Enhanced liver fibrosis score—ELF (Siemens)
The ELF test (Siemens Healthcare Diagnostics Inc) is currently not 
commercially available in the US, but is availble in other countries. 
ELF uses an algorithm that combines three direct serum markers of 
extracellular matrix remodelling and fibrogenesis: hyaluronic acid, 
the N-terminal pro-peptide of collagen type III and tissue inhibitor 
of metalloproteinase-1.73,74 The ELF test has been shown to iden-
tify patients with advanced liver fibrosis with AUROC of 0.92 (95% 
CI: 0.89-0.96), 0.82 for moderate fibrosis and of 0.76 for no fibro-
sis. Advanced fibrosis can be ruled out in primary care settings for 
patients with NAFLD with an ELF score below 10.5. Therefore, the 
National Institute for Health and Care from UK has recommended 
the use of 10.5 as a cut-off point with <10.5 indicating that advanced 
fibrosis in NAFLD is not present and a score of ≥10.5 advanced fi-
brosis (F3 or greater) may be present.74 Furthermore, the 5-year risk 
of death with an ELF score of ≥10.5 seems to be 25%, which is 20 
folds higher compared to those with very low ELF score of <7.7.73,74 
Recent data suggest that ELF thresholds of 9.8 (mid risk of poor out-
come) and 11.3 (high risk of poor outcome) are clinically pertinent; 
however, these values were obtained from a study using patients 
with mixed liver disease aetiologies. Hence, further study is needed 
F I G U R E  1   Guidelines for primary care physicians and diabetologists’ referral to hepatology
Primary Care and Diabetology Practices
For those without blood tests, liver enzymes
should be performed
For those with elevated AST and ALT - other
casues of liver disease should be excluded and US
should be performed (if imaging is not available)
1.
2.
3.
mg/dL in men/< 50 mg/dL in women; BP systolic≥ 130 mm Hg or and/or diastolic ≥ 85 mm Hg.) or 
T2DM with one additional component of metabolic syndrome (WC > 40 inches in men/35 inches in women; Triglycerides≥ 150 mg/dL; HDL < 40
4.
mg/dL in women; Elevated fasting glucose ≥ 100 mg/dL; BP systolic≥ 130 mm Hg or and/or diastolic ≥ 85 mm Hg)  
Non-diabetics with 3 components of MS (WC > 40 inches in men/35 inches in women; Triglycerides≥ 150 mg/dL; HDL < 40 mg/dL in men/<50
History of chronic elevation of AST or ALT (1.5-times ULN for ≥6 months) or
History of fatty liver by any radiologic modality (US, CT, MRI) or liver biopsy (any historical tesr will be sufficient)
https://WWW.mdcalc.com/fibrosis-4-fib-4-index-liver-fibrosisFIB-4 
FIB-4<1.3 FIB-4≥1.3*
Link to Care for Further Assessment
TE
Management of CV risks through life style modification
and appropriate treatment
Serum biomarkers (?ELF when available)
Follow up by primary care
AST,aspastate aminotransferase; ALT,alanine a minotransferase; ULN,upper limit of normal; WC,waist circumference; HDL,high-density lipoprotein cholesterol; US-ultrasound; CT-computed topograohy; MRI-magnetic resonance imaging; BMI-body mass index; FIB-4-fibrosis score four;
CV-cardiovascular; TE,transient elastography; BP,blood pressure. * ≥2.0 inthose 65 years and older
NAFLD with low FIB-4: Management of CV risk through
life style modification and appropriate treatment
•
•
•
•
•
•
( )
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to determine the accuracy of these cut-off values in patients with 
NAFLD.75 If this test becomes clinically available, it will provide a 
non-invasive means to risk stratify those NAFLD patients who are at 
highest risk for adverse outcomes.
7.5 | FibroTest (aka, NASH Fibrosure)
FibroTest (Biopredictive) is a commercially available algorithm that 
combines age, gender, alpha-2-macroglobulin, haptoglobin, apolipo-
protein, total bilirubin and gamma-glutamyl transferase (GGT). The 
current recommended cut-off for advanced fibrosis (F3>) is 0.58.76-79 
The formula for Fibrotest is quite complicated, and due to the varia-
bility of components assays and analysers, FibroTest assays can only 
be performed in validated laboratories. FibroTest is commercially 
available as the ‘NASH Fibrosure’ test in the US, and most commer-
cial laboratories report the results accompanied by an interpretation 
aid and precautions for use. The current cut-offs for F3 is 0.59-0.72 
and for F3/F4 is ≥0.73. An important limitation of this test is related 
to the fact that it was developed to determine fibrosis in those with 
hepatitis C and has not been fully validated in all NASH subpopula-
tions. Until further evidence becomes available, we do not recom-
mend its use as a first-line test for patients with NASH.77-79
7.6 | Fibrometer
The Fibrometer (Echosens) is also a commercial test that is com-
prised of age, AST, ALT, platelet count, weight, alpha-2-macroglob-
ulin, GGT, prothrombin index and urea. There are two versions of 
the Fibrometer test but both have similar results. For the V2G at a 
value of 0.385 (value suggested for the presence of fibrosis stage 
3 or greater), the PPV is 58% and the NPV is 93%. For the V3G at a 
value of 0.461 (value suggested for the presence of fibrosis stage 
3 or greater), the PPV is 55% and the NPV is 94%. Both have an 
accuracy of at least 80% and an AUROC for a fibrosis score of 3 or 
greater of 0.88 and for a fibrosis score of 4, the AUROC is 0.95.79 
Fibrometer also has the same limitations as the Fibrotest as it has 
not been extensively validated in those with NASH and its subpopu-
lations. Similarly, until further evidence of its validation, we do not 
recommend it as a first-line test at this time.
8  | NON-INVA SIVE TESTS IN PATIENTS 
WITH T YPE 2 DIABETES MELLITUS
Given the high prevalence of advanced NASH in patients with 
T2DM, identification of patients with T2DM who are at risk for 
progressive liver disease will be important. In this context, a recent 
study conducted among patients with NAFLD and T2DM found that 
many of the serum-based tests were not accurate in patients with 
T2DM. In fact, the FibroTest in NAFLD patients with T2DM has an 
AUROC of only 0.72 (95% CI: 0.61 to 0.83) for establishing diagnosis 
of advanced fibrosis. This study, in addition to others, highlights 
the importance of developing validated algorithms that combines 
serum-based and radiologic NITs for NASH-fibrosis in patients with 
T2DM. In fact, a relatively recent test, serum PRO-C3 test, may be of 
interest. Serum PRO-C3 which consists of procollagen plasma frag-
ments of propeptides type III may be superior in NAFLD patients 
with T2DM with an AUROC for moderate-to-advanced fibrosis 
noted to be 0.81 (95% CI: 0.74-0.88) and the AUROC for advanced 
fibrosis noted as 0.88 (95% CI: 0.80-0.95). Currently, Pro-C3 is not 
commercially available in the United States and is considered an in-
vestigational NIT for patients with NASH.79
9  | R ADIOGR APHIC A SSESSMENT OF 
FIBROSIS IN NA SH
Radiographic assessment for the degree of fibrosis is based on de-
termining liver stiffness as a surrogate marker for fibrosis Table 2. 
Currently, several methods for assessment of liver stiffness are avail-
able (Table 2) for use in the clinical setting. However, cost and/or 
limited availability of equipment and qualified personnel limit the 
use of radiological tests in routine practice when advanced fibrosis 
is suspected based on assessment by serum marker/s.
9.1 | Vibration-controlled transient elastography 
(VCTE)
Vibration-controlled transient elastography (Fibroscan®—Echosens) 
uses an ultrasound-based technique in which a low-frequency 
(50 Hz) elastic shear wave is generated by a hand-held transducer. 
As the shear wave spreads through the hepatic parenchyma, it meas-
ures a volume of the liver that is 100 times larger than a liver biopsy 
sample. The speed of propagation is proportional to the stiffness 
of the crossed tissue and its measurement can, through specific 
software, provide liver stiffness measurement (LSM) expressed in 
kilopascal (kPa). Based on the manufacturer's recommendation, all 
patients are first scanned by applying the M probe (3.5 MHz) over 
the area of abdomen at the location of the right liver lobe. Patients 
may need to be re-scanned using the XL probe (2.5 MHz) if a deter-
mination is made by the machine.80 The final value is the median of 
10 valid measurements reported in kPa as described above. A cut-off 
of 9.9 kPa or greater for predicting advanced NAFLD-related fibrosis 
is reported to be 95% sensitive and 77% specific, with an AUROC of 
0.93 (95% CI: 0.86-0.96).81
However, other cut-off values have also been suggested which 
have AUROC's of 0.90. These values range from 8.2 kPa for fibrosis 
stage 2, 9.7 kPa for fibrosis stage 3 and 13.6 kPa for fibrosis stage 
4.84 Although, it is possible that the greatest utility of Fibroscan is its 
ability to predict the absence of advanced fibrosis such that a normal 
or mildly elevated score of kPa <6.9 produces a NPV = 95%.85,86
However, VCTE may produce indeterminate results when defining 
the presence of mild-to-moderate fibrosis for approximately 30% of 
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patients due to a variety of reasons which include performing the test 
in a patient who has not fasted for preferably four hours (not fasting 
can produce an artificially high estimate of fibrosis), operator error or 
the use of the incorrect probe for the patients. Specifically, in regard 
to patient's size, an XL probe is suggested for use especially when a 
patients' skin-liver capsule distance (SCD) is ≥25 mm. VCTE combined 
with Fibrometer achieved a PPV of 84% for significant fibrosis (≥F2 
fibrosis) and PPV of 89% for advanced fibrosis (≥F3 fibrosis). However, 
it is important to note that there can be a reported technical failure rate 
of approximately 10%-16% (variables associated with failure: women, 
TA B L E  2   Available radiologic tests for NAFLD/NASH
Test Description Advantage Disadvantage
Ultrasound ○ Used to assess only for the 
presence of steatosis
○ Good for detection of moderate-
to-severe steatosis
○ Widely available
○ Low cost
○ Safe
○ Unable to detect mild steatosis
○ Not quantitative
○ Fibrosis and steatosis have similar 
appearance
○ Operator dependent
○ Accuracy influenced by BMI
Vibration-
controlled 
transient 
elastography 
(VCTE)
○ An ultrasound-based technique 
using a low-frequency (50 Hz) 
elastic shear wave generated by a 
transducer
○ Measures a volume of the liver 
that is 100 times larger than a liver 
biopsy sample.
○ The speed of propagation is 
proportional to the stiffness of the 
crossed tissue
○ Specific software, provide values 
of liver stiffness expressed in 
kilopascal (kPa)
○ A kPa value >9.7 and 13.6 suggests 
F3 and F4 fibrosis respectively
○ Can be performed in clinic with 
real-time results
○ TE has a fairly high failure rate (up to 
35%) when determining the presence 
of mild-to-moderate fibrosis even when 
using the XL probe
○ Expensive device
○ Use is limited in the setting of 
congestive hepatopathy, ascites and 
potentially other liver failure states
Acoustic 
radiation force 
impulse (ARFI)
○ Operator selects the site for the 
liver stiffness measurement using 
real-time B-mode ultrasonography
○ Can be integrated into a 
conventional ultrasound
○ Allows localisation of the shear 
wave to avoid blood vessels and 
ribs
○ Increased failure rate with obesity
○ Cut-off values for advanced fibrosis 
vary significantly (1.15-2.04 m/s)
Supersonic 
shear imaging 
(SSI)
○ SSI transducer emits several wave 
fronts at increasing depth,
○ Uses a frequency band ranging 
from 60 to 6000 Hz
○ Allows a real-time colour mapping 
of the elasticity
○ When integrated into a standard 
B-mode image, a quantitative 
representation of the tissue 
elasticity is generated
○ Can be used with ARFI
○ Similar cut-off values as FibroScan
○ Increased failure rate with obesity
○ Cut-off values for advanced fibrosis 
vary significantly
○ Accuracy of SWE is affected by 
interobserver variation and food intake
○ Measurements should be performed by 
very experienced radiologists
○ Patients are required to fast at least 2 h 
prior to the procedure
Magnetic 
resonance 
elastography 
(MRE)
○ Combines the advantages of MR 
with elastography to provide 
information about the liver tissue 
texture
○ Allows the assessment of the entire 
liver rather than a small part
○ Accurate in obese patients
○ Examines the entire liver
○ Expensive and time consuming 
(although cost and time can be 
reduced significantly with protocol 
modifications)
○ Limited availability
FAST ○ Combines liver stiffness results 
obtained from FibroScan 
measurements, amount of steatosis 
present obtained through the 
controlled attenuation parameter 
(CAP™) measurement combined 
with the amount of inflammation 
present obtained through the 
blood serum value of aspartate 
aminotransferase (AST)
○ Can be calculated at the beside 
using MyFibroscan app
○ As the score increases the 
number of screen failure rates 
and the number of biopsies were 
reduced
○ As the score increases so does the 
number of missed cases
○ Work in still ongoing to determine the 
most appropriate cut-off scores to use 
when determining advanced fibrosis
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adults age >50, the presence of type 2 diabetes mellitus and/or hyper-
tension, operator experience) in which the clinician must decide what 
test would be most appropriate to determine fibrosis.82 Similarly, the 
data obtained by VCTE can be combined with serum AST to provide 
the FAST score, as described below.83
In addition to liver stiffness, some of the elastography tools can 
also quantify hepatic fat. In fact, Fibroscan can provide hepatic fat 
estimation using controlled attenuation parameter (CAP).84,87 In one 
study, CAP was used to determine the presence of liver steatosis 
with AUROC's of 0.87% (95% CI: 0.82-0.92).84
9.2 | Acoustic radiation force impulse (ARFI—
Siemens medical solutions, Mountain View, CA)
In ARFI, the elastography system is integrated onto an ultrasound 
machine, allowing the operator to select the site of LSM through a 
real-time B-mode ultrasonography, and localise the shear wave to 
avoid blood vessels and ribs. ARFI uses short-term acoustic pulses 
to produce shear waves with the results expressed in m/s. When 
ARFI is being performed, the patient is asked to hold their breath 
for short periods of time. ARFI has an AUROC of 0.77 for significant 
fibrosis, 0.84 for advanced fibrosis and 0.84 for cirrhosis. The cut-off 
values that provided these AUROC's and 90% sensitivity and speci-
ficity were for ≥F3 1.15 m/s (90% sensitivity) and 1.53 m/s (90% 
specificity) while for F4 1.3 m/s (90% sensitivity) and 2.04 m/s for 
90% specificity.88,89
9.3 | Supersonic shear imaging (SSI, Supersonic 
Shear Imagine, Aix-en-Provence, France)
Supersonic shear imaging, sometimes referred to as shear wave elastog-
raphy (SWE) is also built on an ultrasound platform. The SSI transducer 
emits several wave fronts at increasing depth, with a frequency band 
ranging from 60 to 6000 Hz, which allows one to remotely generate 
and follow a transient plane shear wave that is propagating in vivo in 
real time. The same probe receives, at high frequency, the propagation 
speed data from the shear waves, allowing for the updating, in real time, 
of the received data. Each sequence of three shear wave fronts lasts 
approximately one second. The LSM is estimated from the shear wave 
local velocity. The radial forces that generate the shear wave are fo-
cused at increasing depths, causing a shear real-time colour mapping 
of the elasticity that is generated and when integrated in a standard 
B-mode image, allows a quantitative representation of the tissue elas-
ticity. Liver stiffness measurement is estimated from the. The final LSM 
value is the average of many shear wave local velocities. Supersonic 
shear imaging, provides a sensitivity of 90% and a specificity of 88% for 
detecting advanced fibrosis (F3 or F4).90,91
In a recent prospective study, the three elastographic methods 
were compared on staging fibrosis among 291 patients with biopsy 
characterised NAFLD. The results showed ROC's for advanced fibro-
sis (F3) of 0.89 (SSI), 0.86 (FibroScan) and 0.84 (ARFI), and for cirrhosis 
(F4) were 0.88 (SSI), 0.87 (FibroScan) and 0.84 (ARFI). Obesity (BMI 
>30 kg/m2), a waist circumference ≥102 cm or increased chest or 
abdominal wall thickness were associated with technical failure on 
determining the LSM with SSI or FibroScan, and the results were un-
reliable with use of ARFI. Both SSI and Fibroscan had sensitivity of 
>90%, with similar cut-off values for ≥ (6.3 and 6.2 kPa) for ≥F3 (8.3 
and 8.2 kPa) and for F4 (10.5 and 9.5).92 As VCTE is portable and can 
be performed in the clinic by a registered nurse and the equipment 
is internationally calibrated across different manufacturers, this re-
mains the tool of choice for use in routine practice on assessment of 
fibrosis in patients with NAFLD.
9.4 | Magnetic resonance elastography (MRE)
MRE combines the advantages of MR with elastography to provide 
information about the liver tissue texture which allows the assess-
ment of the entire liver rather than a small part.93-95 Some studies 
have also suggested that MRE may perform better than VCTE for 
identifying earlier degrees of fibrosis (F2). However, both MRE and 
VCTE appear to perform well for identifying stage 3-4 fibrosis with 
ROCs of 0.88 and 0.89 respectively.87,94,95 For MRE, using a cut-off 
of 3.63 kPa for distinguishing between advanced fibrosis (F3-F4) and 
fibrosis stages 0-2 produced an AUROC of 0.924, with a sensitivity 
of 0.86, specificity of 0.91, PPV of 0.68 and NPV or 0.97. It is impor-
tant to note that the stiffness cut-offs for TE and MRE are not the 
same; stiffness greater than 9.9 kPa on TE is predictive of advanced 
fibrosis, whereas the cut-off when using MRE is 3.63 kPa. Practically 
speaking, adding the elastography portion to a standard abdominal 
MRI is uncomplicated for the patient, adding only a minimal incre-
ment of time. More recent studies have suggested the superiority 
of MRE over VCTE in regards to AUROC.72 Nevertheless, the main 
limitations for MRE are the lack of easy access and the learning curve 
required for local radiology centres to become proficient with per-
forming technically adequate MRE procedures. These reasons, along 
with cost and coverage issues, make MRE a suboptimal NIT for large-
scale screening and risk stratification attempts.72
10  | FA ST™
FAST™ is a combination score that can be readily calculated at the 
bedside to determine whether significant fibrosis in NASH is present 
(defined as NAFLD activity score of 4 or higher and fibrosis stage 2 
or higher).83 FAST™ combines liver stiffness results obtained from 
FibroScan measurements (LSM), degree of steatosis obtained through 
the Fibroscan's controlled attenuation parameter (CAP™) measure-
ment, and the degree of hepatic inflammation assessed by the serum 
AST value. Examination with FibroScan and the blood collection for 
AST should be within 6 months of each other. A single score can be 
generated and interpreted by the healthcare provider at the bedside 
through the MyFibroscan™ app. In the score development study, 
an AUROC of 0.80 was obtained while in the validation cohort the 
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AUROC was 0.85. The FAST score ranges between 0 and 1. In its 
validation cohort, investigators found that as the score increased, 
the likelihood of mild fibrosis decreased and the number of biopsies 
needed was reduced; however, as the score increased so did the num-
ber of missed cases. Additionally, FAST does not replace the need for 
exercising clinical judgement, given that low FAST scores can some-
times be obtained despite the presence of abnormal liver stiffness.96 
FAST may provide the most utility with liver stiffness scores between 
5 and 10 kPa. The FAST cut-off value for specificity (≥0.90) was 0.67 
in the derivation cohort with a positive predictive value (PPV) of 0.83 
(95% CI 0.75-0.87), which is the ‘rule-in zone’ for predicting NASH 
with significant fibrosis. Work is still ongoing to determine the most 
appropriate cut-off scores to use when determining advanced fibrosis.
11  | CLINIC AL SCENARIO IN PRIMARY 
C ARE OR DIABETOLOGY PR AC TICE 
SET TINGS
There are several clinical practice scenarios in which the possibility 
for NAFLD is present and in which the patient should be evaluated 
for NAFLD with recommendations for when to refer to a specialist 
(Figure 1). One such scenario is when a patient presents with persistent 
(≥6 months) unexplained elevation in aminotransferases (AST or ALT) 
defined as ≥1.5 times the upper limit of normal (normal ALT levels are 
defined as 19-25 U/L for women and 29-33 U/L for men94). In this case, 
an ultrasound of the liver should be obtained and other causes of liver 
disease such as alcohol-related, viral hepatitis, autoimmune liver dis-
ease, hemochromatosis, alpha-1-antitrypsin deficiency and medication-
related liver injury need to be excluded. Once fatty liver is established 
and other causes of liver disease are excluded, the next step is to risk 
stratify NAFLD patients to high or low risk based on the FIB-4 score. 
A FIB-4 score can be calculated at https://www.mdcalc.com/fibro sis-
4-fib-4-index -liver -fibrosis. The patient should be referred to a special-
ist (gastroenterologist/hepatologist) if the FIB-4 ≥1.3 (≥2.0 in those 
65 years and older) for further evaluation and treatment if deemed 
necessary. If the FIB-4 score is <1.3 (<2.0 in those 65 years and older), 
the patient should remain under primary care monitoring and receive 
appropriate treatment to manage cardio-metabolic risk factors through 
life style modification as well as wellness counselling (diet and exercise).
Another scenario is when a patient is incidentally found to have 
a fatty liver on imaging (sonography, CT, MRI) which had been per-
formed for other reasons. In this case, liver enzyme levels should be 
checked, and the FIB-4 score should be determined and followed as 
outlined above and in the Figure 1.
Given the very high prevalence of NAFLD and NASH in patients 
with T2DM, patients with T2DM should be suspected of having 
NAFLD. In this context, presence of T2DM with additional metabolic 
risks will increase both the prevalence of NASH and the likelihood of 
progressive liver disease. Therefore, the Council recommends that 
patients with T2DM and one additional component of metabolic syn-
drome be assessed with FIB-4 and liver enzymes (Figure 1). Given the 
suboptimal accuracy of serum NITs in this population, most of these 
patients may require assessment of liver stiffness which can be pro-
vided after linkage to centers with the expertise. In the absence of 
T2DM, patients with at least three other components of metabolic 
syndrome (obesity, dylipidemia and hypertension) should be screened 
with the FIB-4 and liver enzymes (Figure 1).
As noted previously, if the patient has FIB-4 >1.3 (>2.0 in those 
65 years and older), he/she should be referred to a gastroenterologist/
hepatologist or other practices with expertise in NAFLD (diabetolo-
gists or PCPs with expertise in NASH) for further assessment using 
other NITs (such as ELF when becomes available or transient elastog-
raphy) (Table 3). For those patients who fall into the indeterminant area 
using these initial NITs, MRE can be considered as the next step. In this 
context, MRI-PDFF is highly accurate for determining hepatic fat and 
MR elastography is also quite accurate for measurement of liver stiff-
ness. Finally, liver biopsy should be reserved for those patients with 
suspicion for other coexisting liver disease (such as autoimmune liver 
disease), or when clinically advisable by the specialty assessment.
It is also important to recognise that NAFLD patients (regardless of 
the stage of liver disease) are at significantly increased risk for cardio-
vascular mortality. Therefore, all NAFLD patients must undergo a care-
ful assessment for their 10-year CVD risk. Furthermore, those with 
coexisting cardiometabolic risk factors require early and aggressive 
treatment addressing their respective risk factors as previously noted.
12  | CONCLUSIONS/FINAL 
RECOMMENDATIONS
Already a major cause of liver-related morbidity and mortality, NAFLD 
is increasing in prevalence around the world. As a result, PCPs and dia-
betologists are now the frontline care providers and are being tasked 
with determining who has high-risk NAFLD and should be referred to a 
gastroenterologist or hepatologist for further management. Since he-
patic fibrosis, especially advanced fibrosis, is associated with adverse 
liver-related outcomes, members of the US Members of the Global 
NASH council recommend that PCP's and diabetologists use clinical 
risk stratification to identify which patients are at risk for liver fibro-
sis. This identification includes screening patients with T2DM using 
TA B L E  3   Quick reference guide for NIT values that suggest 
potential presence of clinically important hepatic fibrosis requiring 
referral to a specialist for further evaluation
NIT
Value for 
referral
FIB-4 >1.3
NFS >−1.45
APRI >1
ELF >9.8
FibroTest >0.58
VCTE >8.2
ARFI >1.15
Abbreviations: ACRI, acoustic radiation force impulse; APRI, AST to 
platelet ratio index; ELF, enhanced liver fibrosis score; FIB-4, fibrosis 4 
test; NFS, NAFLD fibrosis score; VCTE, vibration-controlled transient 
elastography.
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the FIB-4 non-invasive tool and referring to a specialist for FIB-4 ≥1.3 
(≥2.0 in those 65 years and older). In addition, patients who do not have 
T2DM but have at least three other components of metabolic syn-
drome (waist circumference >40 inches in men/35 inches in women; 
triglycerides ≥150 mg/dL; HDL <40 mg/dL in men/<50 mg/dL in 
women; elevated fasting glucose ≥l00 mg/dL; blood pressure systolic 
≥130 mm Hg or and/or diastolic ≥85 mm Hg.) should also be screened 
with the FIB-4 and a FIB-4 score ≥1.3 (≥2.0 in those 65 years and older) 
should generate a referral to a specialist for further evaluation.
However, a purely ‘liver-centric’ approach to NAFLD/NASH is 
not sufficient so treatment of NAFLD/NASH needs to shift to a more 
patient-centred, multidisciplinary team-based approach. Since more 
patients with NAFLD will die from CVD complications rather than 
the consequences of their liver disease, it is necessary that PCPs and 
diabetologists provide a careful assessment of the 10-year CVD risk 
for all persons with NAFLD as well as providing early and aggressive 
treatment for all coexisting cardiometabolic risk factors.
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